BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19839918)

  • 1. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
    Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
    Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
    Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
    Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
    Souglakos J; Kakolyris S; Vardakis N; Androulakis N; Mavroudis D; Vamvakas L; Kouroussis C; Agelaki S; Saridaki Z; Georgoulias V
    Cancer Invest; 2005; 23(6):505-10. PubMed ID: 16203658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
    Saridaki Z; Bozionelou V; Kentepozidis N; Kotsakis A; Vardakis N; Kalykaki A; Gioulbasanis I; Karampeazis A; Vamvakas L; Georgoulias V; Mavroudis D
    Oncology; 2007; 72(1-2):45-50. PubMed ID: 17998790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
    Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
    Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.